🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchPhase 3 trial enrollment guide — my results so far Page 4

Phase 3 trial enrollment guide — my results so far

josh_phd_bmore Mon, Feb 23, 2026 at 12:22 PM 21 replies 1,019 viewsPage 4 of 5
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Feb 27, 2026 at 2:33 PM#16

Adding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

I would rather be corrected than agreed with, if it comes to it.

26 1RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 23 others
Reply Quote Save Share Report
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Feb 27, 2026 at 9:35 PM#17
PeptideSynthNJ said:
Practical: whatever you change, write down the date and the reason.

Adding the part of the answer the thread has not reached. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

25 0TinaHashiRN, robert_kc, dan_philly and 22 others
Reply Quote Save Share Report
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Feb 28, 2026 at 4:37 AM#18

One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

Last edited: Feb 28, 2026 at 6:37 AM
24 24zoe_NC, Dr.ObesityLA, NurseKim_ATL and 21 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Feb 28, 2026 at 11:39 AM#19

One thing that is still open after PeptideSynthNJ’s answer:

Did your prescriber agree with that reading, and if not what was their objection?

23 23kate.chem, DataDave, Dr.GutHealth and 20 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Feb 28, 2026 at 6:42 PM#20

Moderator note: a couple of off-topic posts removed. No action needed from anybody.

Last edited: Feb 28, 2026 at 8:42 PM
1 1PurityPaulOR
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register